Vedbæk, October 16, 2007: Exiqon signs a cooperative research and development agreement for cancer diagnostics with The National Cancer Institute

Vedbæk, September 28, 2007: Exiqon A/S' share capital and total number of voting rights

Copenhagen, September 24, 2007: Articles of Association of EXIQON A/S

Vedbæk, September 24, 2007: Exiqon A/S increases its share capital in connection with exercise of warrants

Vedbæk, September 18, 2007: Per Wold-Olsen to join Exiqon A/S Board of Directors

Copenhagen, August 31, 2007: Report regarding the managements’ and closely related parties’ transactions with securities in Exiqon A/S

Vedbæk, August 28, 2007: Exiqon - Interim report for the first 6 months of 2007 (unaudited)

Vedbæk, July 10, 2007: Luminex and Exiqon sign distribution agreement for microRNA products and launch expanded product line

Copenhagen, June 4, 2007: Major shareholders announcement pursuant to section 29 of the Danish Securities Trading Act

Copenhagen, June 1, 2007: Exiqon A/S' share capital and total number of voting rights June 1st. 2007

Copenhagen, June 1, 2007: Articles of Association of EXIQON A/S

Copenhagen, May 31, 2007: Danske Markets exercises the overallotment option for 1,303,500 shares in Exiqon A/S. The gross proceeds to the company will be approximately DKK 52.1 million.

Copenhagen, May 29, 2007: Exiqon A/S’ planned dates for financial reporting the next 12 months.

Copenhagen, May 29, 2007: Report regarding the managements’ and closely related parties’ transactions with securities in Exiqon A/S.

Copenhagen, May 25, 2007: STRONG INTEREST IN SUBSCRIBING FOR SHARES IN EXIQON A/S. OFFERING WAS SUBSCRIBED MORE THAN 7 TIMES.

Copenhagen, May 24, 2007: Exiqon A/S closes its initial public offering to applications for shares for more than DKK 2 million.

Copenhagen, May 22, 2007: Exiqon A/S closes its initial public offering for applications for shares up to and including DKK 2 million.

Copenhagen, May 14, 2007: Today, Exiqon A/S publishes a prospectus in connection with its intended flotation on the Copenhagen Stock Exchange. The shares are offered in the price range DKK 32 to DKK 42 per share. The company will host an information meeting today, 14 May, at 2.00 pm (Copenhagen time) at the Hotel D'Angleterre, Kongens Nytorv 34, DK-1022 Copenhagen, Denmark, at the Louis XVI room.

Copenhagen, May 2, 2007: Exiqon is considering a potential IPO and elects Thorleif Krarup new Chairman of its Board of Directors. Exiqon is a biotechnology company whose core business is to develop, manufacture and market products for molecular biology analyses. Exiqon already markets a number of products and generated revenue of DKK 43 million in 2006. The customers primarily include companies in the pharmaceutical, diagnostic and agrotechnology industries and research institutions in the field of molecular biology.

February 7, 2007: COPENHAGEN, Denmark - Exiqon A/S, a leading supplier of high-value gene expression analysis products today announced the appointment of 4 new distributors covering Italy, Spain, South Korea, Australia and New Zealand. The new distributors will focus on Exiqon’s growing and very successful miRCURYä LNA product line for microRNA analysis.

December 18, 2006: AUSTIN, Texas and COPENHAGEN, Denmark - Luminex® Corporation (Nasdaq: LMNX), a leading multiplex solution developer, and Exiqon A/S, today announced the launch of FlexmiR, a new line of microRNA products that can provide more than 6,300 data points in just four hours.

September 19, 2006, Austin, Texas and Copenhagen, Denmark - Luminex® Corporation (NASDAQ: LMNX), a leading multiplex solution developer, and Exiqon A/S, announced today the signing of an agreement to co-develop and commercialize microRNA products. Exiqon will develop and manufacture microRNA products on behalf of the Luminex Bioscience Group (LBG) based on Luminex's xMAP® technology and Exiqon's Locked Nucleic Acid (LNA™) technology.

September 12, 2006. Exiqon A/S, today announced it is expanding its US presence by opening a sales, distribution and technical support facility in the heart of the Boston, MA biotech community.

Copenhagen, July 27, 2006: Exiqon A/S today announced that it has secured the rights to use over 200 human and viral microRNA sequences in diagnostic applications, through two separate co-exclusive license agreements with Garching Innovation, the technology transfer agency of the Max Planck Society, and The Rockefeller University. The new licenses enable Exiqon to expand into the development of diagnostic products.

Copenhagen, June 29, 2006: Exiqon A/S today announced the appointment of 4 new distributors covering Japan, Singapore and China. The new distributors will focus on Exiqon's growing and very successfull miRCURY™ LNA product line for microRNA analysis.

January 31, 2006: Exiqon A/S, a leading supplier of high-value gene expression analysis products, announced today it is participating in a microRNA research consortium supported by a USD 1.6 million grant from The Danish Ministry of Science Technology and Innovation to develop new microRNA diagnostic tools.

January 4, 2006: Exiqon A/S a leading supplier of high-value gene expression analysis products announced today the appointment of Michael Kallelis as President and General Manager of Exiqon's new operations.

November 29, 2005: Exiqon A/S today announced the launch of their miRCURY™ Array for highly sensitive profiling of miRNAs in human, mouse and rat.

November 29, 2005: Exiqon A/S today announced the launch of their miRCURY™ Array Labelling kit for highly uniform labelling of microRNAs.

November 22, 2005: The Ernst & Young award follows a successful past year where the Exiqon CEO won the award as Biotech Builder of the year, and Exiqon was named among the Top 100 most Innovative companies worldwide by the magazine RedHerring.

June 2, 2005: The Danish biotech company Exiqon A/S has completed a third round of financing providing USD 20 million in additional funding.

May 26, 2005: On Thursday May 26 th at 2pm EST, the manuscript entitled "MicroRNA Expression in Zebrafish Embryonic Development" from Dr. Ronald H. Plasterk's group of the Hubrecht Laboratory at Netherlands Institute for Developmental Biology, Utrecht, The Netherlands was published by the prestigious journal Science.

May 17, 2005: Roche Diagnostics and Exiqon, Vedbæk, Denmark, a provider of high-value gene expression analysis products, today announced the signing of an agreement naming Roche Diagnostics as sole distributor of Exiqon's ProbeLibrary Kits.

May 17, 2005: Copenhagen, Denmark - Exiqon today announced the launch of their miRCURY™ Detection product series for detection of microRNAs by fluorescence in situ hybridization (FISH) and Northern Blot analysis.

February 25, 2005: Denmark- Exiqon today announced the signing of a license agreement with Invitrogen Corporation to incorporate Exiqon’s Locked Nucleic Acid (LNA™) chemistries into reagent kits for nucleic acid (RNA and DNA) sample preparation.

December 9, 2004: Exiqon A/S, a leading supplier of high-value gene expression analysis products announced today that it has been selected as a Top 100 Innovator by the renowned media company Red Herring.

May 18, 2004: The ProbeLibrary(tm) product series is a range of kits for real time PCR expression analyses of virtually any transcript. First kits will cover human and mouse.

April 14, 2004: U.S. Genomics and Exiqon have entered into a worldwide license agreement to incorporate Exiqon’s Locked Nucleic Acid (LNA™) chemistries into reagent kits for the U.S. Genomics Trilogy™ platform.

June 6, 2003: Nunc A/S and Exiqon A/S have signed an agreement whereby Exiqon licence proprietary Anthraqinone coating technology to Nunc for the production of MicroWell based activated surfaces. Thereby, Nunc releases 26 new products in June 2003.